文献速递类风湿关节炎

巴瑞替尼治疗类风湿关节炎2年影像学结构损伤进展率低

Low rates of radiographic progression of structural joint damage over 2 years of baricitinib treatment in patients with rheumatoid arthritis.
PubMed 文献 · RMD Open · 2019-05-10

基于三项III期试验及其长期延伸研究,评估巴瑞替尼治疗2年对类风湿关节炎患者影像学结构损伤进展的影响。在DMARD初治、csDMARD-IR及MTX-IR患者中,初始巴瑞替尼治疗者的影像学进展比例均显著低于初始MTX或安慰剂,与初始阿达木单抗相似。

要点

  • DMARD初治患者2年无进展比例:巴瑞替尼4mg+MTX 87.3% vs MTX 70.6%,p≤0.001。
  • MTX-IR患者无进展比例:巴瑞替尼4mg 82.7% vs 安慰剂70.6%,p≤0.001;与阿达木单抗83.5%相似。
  • csDMARD-IR患者无进展比例:巴瑞替尼4mg 87.2% vs 安慰剂73.2%,p≤0.01。

核心结论

  • 每日一次巴瑞替尼治疗可使类风湿关节炎患者影像学进展率在2年内保持较低水平。

研究设计与样本

  • 研究纳入完成三项III期试验并进入长期延伸研究的类风湿关节炎患者,继续原巴瑞替尼剂量。
  • 分析人群为2573例随机患者中进入长期延伸研究的2125例(82.6%)里的1893例(89.1%)。
  • 基线、第1年和第2年X线采用van der Heijde改良Total Sharp Score评分,缺失数据用线性外推法处理。

主要发现

  • DMARD初治患者第2年无进展(≤SDC)比例:巴瑞替尼4mg+MTX 87.3%,MTX 70.6%,p≤0.001。
  • MTX-IR患者第2年无进展比例:巴瑞替尼4mg 82.7%,阿达木单抗83.5%,安慰剂70.6%,p≤0.001。
  • csDMARD-IR患者第2年无进展比例:巴瑞替尼4mg 87.2%,安慰剂73.2%,p≤0.01。

关键数值与推荐

  • 影像学无进展定义为变化≤最小可检测变化(SDC)。
  • DMARD初治患者中,初始巴瑞替尼(单药或联合)第2年进展显著低于初始MTX(p≤0.001)。
  • MTX-IR患者中,初始巴瑞替尼进展显著低于初始安慰剂(p≤0.001),与初始阿达木单抗相似。
  • csDMARD-IR患者中,巴瑞替尼4mg较安慰剂显著获益(p≤0.01)。

临床怎么用

  • 对于DMARD初治、csDMARD-IR或MTX-IR的类风湿关节炎患者,巴瑞替尼治疗2年可抑制影像学结构损伤进展。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate radiographic progression of structural joint damage over 2 years in patients with rheumatoid arthritis from baricitinib clinical trials who were disease-modifying antirheumatic drug (DMARD)-naïve or had an inadequate response to conventional synthetic DMARDs (csDMARD-IR). METHODS: Patients had completed one of three phase III studies and entered a long-term extension (LTE) study, continuing on the same baricitinib dose as at originating study completion. At 52 weeks, DMARD-naïve patients receiving methotrexate (MTX) or combination therapy (baricitinib 4 mg+MTX) were switched to baricitinib 4 mg monotherapy (±MTX per investigator opinion); MTX-IR patients receiving adalimumab were switched to baricitinib 4 mg on background MTX. At 24 weeks, csDMARD-IR patients receiving placebo were switched to baricitinib 4 mg on background csDMARD. Radiographs at baseline, year 1 and year 2 were scored using the van der Heijde modified Total Sharp Score. Linear extrapolation was used for missing data. RESULTS: Of 2573 randomised patients, 2125 (82.6%) entered the LTE, of whom 1893 (89.1%) entered this analysis. At year 2, progression was significantly lower with initial baricitinib (monotherapy or combination therapy) versus initial MTX in DMARD-naïve patients (proportion with non-progression defined by ≤smallest detectable change (SDC): 87.3% baricitinib 4 mg+MTX; 70.6% MTX; p≤ 0.001). In MTX-IR patients, progression with initial baricitinib was significantly lower than with initial placebo and similar to initial adalimumab (≤SDC: 82.7% baricitinib 4 mg; 83.5% adalimumab; 70.6% placebo; p≤0.001). In csDMARD-IR patients, significant benefit was seen with baricitinib 4 mg (≤SDC: 87.2% vs 73.2% placebo; p≤0.01). CONCLUSIONS: Treatment with once-daily baricitinib resulted in low rates of radiographic progression for up to 2 years.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. van der Heijde D, Schiff M, Tanaka Y, et al. Low rates of radiographic progression of structural joint damage over 2 years of baricitinib treatment in patients with rheumatoid arthritis. RMD Open. 2019. PMID: 31168413. doi:10.1136/rmdopen-2019-000898

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。